Key result
Nesiritide was used in two infants during ECMO to control mean arterial pressure (up to 0.09 µg/kg/min) and augment urine output (0.01-0.03 µg/kg/min).
Why the study?
Does nesiritide control mean arterial pressure or augment urine output in infants during ECMO?
Case Report (n=2)
Does nesiritide control mean arterial pressure or augment urine output in infants during ECMO?
Nesiritide may have potential applications for blood pressure control and diuresis in infants undergoing extracorporeal membrane oxygenation.
Hypothesis-generating for nesiritide in infant ECMO; prospective trials needed before any clinical consideration.
Nesiritide is a recombinant formulation of B-type natriuretic peptide (BNP). Preliminary experience in the adult population has shown nesiritide to be an effective agent in the treatment of decompensated congestive heart failure (CHF) in adults. Given its physiological effects, it may be an effective agent in other clinical scenarios. We report the use of nesiritide in two infants during extracorporeal membrane oxygenation (ECMO). In one patient, nesiritide in doses up to 0.09 microg.kg(-1).min(-1) were used to control mean arterial pressure while in the other patient, doses of 0.01-0.03 microg.kg(-1).min(-1) were used to augment urine output. The potential applications of nesiritide and dosing regimens for this agent in the ECMO population are discussed.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2004) conducted a case report in Infants on extracorporeal membrane oxygenation (ECMO) (n=2). Nesiritide was evaluated on Mean arterial pressure control and urine output augmentation. Nesiritide was used in two infants during ECMO to control mean arterial pressure (up to 0.09 µg/kg/min) and augment urine output (0.01-0.03 µg/kg/min).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: